Biosimilars and the extrapolation of indications for inflammatory conditions
John RP Tesser,1 Daniel E Furst,2 Ira Jacobs3 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2UCLA Health, Los Angeles, CA, 3Pfizer Inc, New York, NY, USA Abstract: Extrapolation is the approval of a biosimilar for use in an indication held by the originator biologic not directly...
Guardado en:
Autores principales: | Tesser JRP, Furst DE, Jacobs I |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3ad9986b0aed40c098ffc77ac331ae22 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A practical guide about biosimilar data for health care providers treating inflammatory diseases
por: Markenson J, et al.
Publicado: (2017) -
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais E, et al.
Publicado: (2020) -
Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq
por: Al Ani NA, et al.
Publicado: (2018) -
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald T, et al.
Publicado: (2021) -
Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study
por: Benjamin Kearns, et al.
Publicado: (2021)